Tropomyosin (TM) family of cytoskeletal proteins is implicated in stabilizing actin micro®laments. Many TM isoforms, including tropomyosin-1 (TM1), are downregulated in transformed cells. Previously we demonstrated that TM1 is a suppressor of the malignant transformation, and that TM1 reorganizes micro®la-ments in the transformed cells. To investigate how TM1 induces micro®lament organization in transformed cells, we utilized ras-transformed NIH3T3 (DT) cells, and those transduced to express TM1, and/or TM2. Enhanced expression of TM1 alone, but not TM2, results in re-emergence of micro®laments; TM1, together with TM2 remarkably improves micro®lament architecture. TM1 induced cytoskeletal reorganization involves an enhanced expression of caldesmon, but not vinculin, aactinin, or gelsolin. In addition, TM1-induced cytoskeletal reorganization and the revertant phenotype appears to involve re-activation of RhoA controlled pathways in DT cells. RhoA expression, which is suppressed in DT cells, is signi®cantly increased in TM1-expressing cells, without detectable changes in the expression of Rac or Cdc42. Furthermore, expression of a dominant negative Rho kinase, or treatment with Y-27632 disassembled micro®laments in normal NIH3T3 and in TM1 expressing cells. These data suggest that reactivation of Rho kinase directed pathways are critical for TM1-mediated micro®lament assemblies. Oncogene (2001) 20, 2112 ± 2121.
Introduction
Expression of many cytoskeletal proteins is downregulated during neoplastic transformation, resulting in an altered cell morphology, reorganization of cytoarchitecture, cell motility, and possibly contributing to changes in gene expression by modulating intracellular signaling pathways (Button et al., 1995; Janmey and Chaponnier, 1995) . For example, many micro®lament associated proteins such as a-actinin, vinculin, gelsolin and tropomyosins (TMs) are suppressed to varying degrees in many transformed cells (Ben-Ze'ev, 1997) . Furthermore, restoration of these proteins inhibits the malignant phenotype of many dierent experimentally transformed cell lines, underscoring the pivotal role of cytoskeletal organization in maintaining a normal phenotype (Ayscough, 1998; Janmey and Chaponnier, 1995) . Our laboratory has been interested in understanding the role of cytoskeletal proteins, in particular that of tropomyosins, in malignant transformation.
Tropomyosin (TM) family comprises of 5 ± 7 dierent closely related isoforms, whose expression is altered in many transformed cells (Lin et al., 1997; Pittenger et al., 1994) . For example, suppression of high M r TMs, viz., isoforms 1 and 2 (TM1 and TM2, respectively), is nearly universal in all the transformed cell lines tested, while elevated levels of the low M r species such as TM4 and TM5 are reported in some malignant cell types (Bhattacharya et al., 1990; Cooper et al., 1985 Cooper et al., , 1987 Hendricks and Weintraub, 1981; Leavitt et al., 1986; Matsumura et al., 1983) . Although all TMs bind to actin with varying binding anities, the precise function of each of the isoforms remains largely unknown. Other actin binding proteins, such as caldesmon, also in¯uence TM binding to actin to varying degrees (Pittenger et al., 1995) . Our eorts to elucidate the causal relationship between tropomyosin expression and cell phenotype have uncovered signi®cant fundamental dierences in the roles of TM isoforms in cell physiology (Braverman et al., 1996; Prasad et al., 1993; Shah et al., 1998) .
In DT (v-ki-ras-transformed NIH3T3) cells, TM1 expression is suppressed to 50% levels found in normal ®broblasts, but TM2 levels are essentially undetectable (Cooper et al., 1985; Prasad et al., 1993) . DT cells are spindle shaped with no de®ned micro®lament structures and are highly malignant. Transduction of DT cells with a cDNA encoding TM1 protein results in reorganization of cytoskeleton with well-de®ned micro®laments. More signi®cantly, elevated TM1 levels inhibited the transformed phenotype of DT cells, culminating in a stable revertant phenotype (Braverman et al., 1996; Prasad et al., 1993) . In addition, TM1 also suppresses v-src-induced transformed phenotype, suggesting that TM1 may be a general suppressor of transformation that belongs to class II tumor suppressors (Prasad et al., 1999) . On the contrary, restoration of expression of TM2 protein did not improve the cytoskeleton, and the cells remained transformed, resembling DT cells (Braverman et al., 1996) . Coexpression of TM2 with TM1, however, dramatically improved micro®laments, similar to those in normal NIH3T3 cells: DT cells expressing TM1 and TM2 exhibit a revertant phenotype (Shah et al., 1998) . It is intriguing that TM1, an actin binding protein reorganizes the cytoskeleton and restores the normal growth phenotype, while the other closely related TMs despite their ability to bind to actin are unable to modulate cytoarchitecture and growth phenotypes (Braverman et al., 1996; Pittenger et al., 1994) . While TM1 alone is able to organize the other cytoskeletal proteins into micro®laments to an appreciable degree, together with TM2 it restores the cytoarchitecture to the extent found in normal cells.
The restored cytoskeleton may be important for the anti-oncogenic eects of TM1. In the transformed cells, along with TMs, the expression myosin light chain and many other key micro®lament proteins are also suppressed (Ben-Ze'ev, 1997; Janmey and Chaponnier, 1995; Kumar and Chang, 1992) . To elucidate the nature of TM1-induced formation of micro®laments, we have evaluated the changes in the expression of other key cytoskeletal proteins and tested the stability of TM1-induced cytoskeleton in the DT cell system described above. Reorganization of cytoskeleton, arising from the forced expression of TM1, will have to involve recruitment of some of the other cytoskeletal proteins from the existing pool; alternatively, through yet unknown mechanisms, TM1 might contribute to an increase in their synthesis. Our results, for the ®rst time, show that TM1 reorganizes cytoskeleton via both of these mechanisms. We also provide evidence for the involvement of Rho-regulated pathways, in the emergence of micro®laments. These pathways could play a critical role in modulating gene expression, to culminate in a revertant phenotype.
Results

Expression of cytoskeletal proteins in TM1 mediated reversion
To investigate the role of TMs in cellular transformation, we generated several cell lines of DT expressing TM1 (DT/TM1 cells), TM2 (DT/TM2 cells) or both the TMs (DT/TM1-TM2 cells) by introduction of cDNAs encoding TM1, TM2 or both the TMs, respectively (Table 1; Figure 1 ) (Braverman et al., 1996; Prasad et al., 1991 Prasad et al., , 1993 Shah et al., 1998) . In transformed cells, in addition to TMs, many other proteins including those associated with micro®laments are also suppressed. For example, expression of gelsolin, vinculin, a-actinin and caldesmon is downregulated in many transformed cells and tumors Ben-Ze'ev, 1997; Button et al., 1995; Janmey and Chaponnier, 1995; Mielnicki et al., 1999) . Given the high degree of the malignant nature of DT cells, these changes are expected to be extensive. It should be noted that TM1 and TM2 share extensive homology, yet only TM1 is capable of reorganizing micro®laments and suppressing the Ras-induced transformed phenotype (Braverman et al., 1996; Shah et al., 1998) . The properties of micro®laments induced by TM1 in DT cells could signi®cantly dier because the expression of many components is likely to remain repressed due to the continued oncogenic action of Ras. To understand the molecular basis of reorganization of cytoskeleton in DT/TM1 and DT/TM1-TM2 cells, expression of some of the key micro®lament-associated proteins was investigated in normal NIH3T3, DT, DT cells transduced with an empty pBNC vector (DT/V), DT/TM1, DT/TM2 and DT/ TM1-TM2 cells.
Vinculin expression was signi®cantly lower in DT and the derived cell lines compared to normal ®broblasts (Figure 2a ), a ®nding consistent with the published data (Rodriguez Fernandez et al., 1992) . Immunoprecipitation followed by Western blotting with a speci®c antibody revealed that expression of vinculin remained low in the cell lines derived from DT, regardless of the phenotype. Then we investigated whether TM1 expression modulates distribution of vinculin in focal adhesions by confocal microscopy ( Figure 2b ). The samples were stained with antivinculin antibody optically, sectioned with a confocal microscope and the composite images are presented. In normal NIH3T3 cells, vinculin was well spread through out the cell body and organized as dense particles, indicative of focal adhesions. In DT cells, where a 25 ± 30% reduction in vinculin levels is noted, a dierent organization, consistent with the lack of micro®la-ments, was observed: vinculin is mostly concentrated to the perinuclear area. In DT/TM1 cells, the vinculin staining is more spread out. In cells expressing both TM1 and TM2, however, vinculin was spread more evenly in the cell body, with the presence of`speckled' appearance indicating a better organization. The samples were also stained for the presence of actin ®laments by Texas-Red conjugated phalloidin (data not shown).
Caldesmon, which regulates binding of TMs to micro®laments, is also down regulated in transformed cells. Data of Figure 3a show that expression of caldesmon mRNA is suppressed 40% in DT, DT/V and DT/TM2 cells. However, in DT/TM1 (90%) and DT/TM1-TM2 (&100%) cells caldesmon mRNA expression is nearly restored to the levels found in normal ®broblasts. Caldesmon protein levels were also enhanced in the revertant DT/TM1 and DT/TM1-TM2 cells, compared to the parental DT cells, as determined by immunoblotting (Figure 3b ).
On the other hand, there are no consistent changes in the expression of a-actinin in NIH3T3, DT and the derived cell lines (data not shown). In normal ®broblasts, transformed and the revertant cells, aactinin levels did not change appreciably. However, in cell lines expressing TM2, there appears to be a modest decrease in a-actinin levels. Western blotting with antiOncogene Tropomyosin-1 induced cytoskeleton V Shah et al gelsolin antibody revealed that there is a detectable decrease (in relation to tubulin expression) in the expression in DT and DT/V cells when compared to untransformed cells. Gelsolin levels did not signi®-cantly change in DT/TM1 or DT/TM2, but are enhanced in DT/TM1-TM2 cells, to the levels found in normal ®broblasts (data not shown).
Expression of Rho-family of regulatory proteins
Ras-related Rho family of GTPases is widely recognized as the regulators of cytoskeletal integrity and gene expression (Hall, 1998; Khosravi-Far et al., 1998) . While Rho is implicated in the formation of micro®la-ments, Rac regulates lamellipodia and membrane ruing and Cdc42 induces ®lopodia (microspikes). We investigated whether the observed reorganization and cell spreading involves changes in levels of Rho family of proteins. Immunoprecipitation followed by immunoblotting with anti-RhoA antibodies indicates that RhoA expression is lower in DT cells, while in normal ®broblasts it is readily detectable (Figure 4a ). Similarly in the vector control DT cells and those expressing TM2, RhoA levels remained low. But in the DT/TM1 and DT/TM1-TM2 cells, RhoA expression is increased to normal levels. For control purposes and to test the speci®city, the antibody was ®rst reacted with the immunogen (blocking peptide) and used for immunoprecipitations (data not shown). In these experiments, as expected, no RhoA signal was detected in any of the lysates employed. Western blotting with Rac antibody indicated a modest increase in DT cells, compared to NIH3T3 cells. But no clear-cut changes in Rac expression were discernible (Figure 4b ). Immunoprecipitation and immunoblotting with anti-Cdc42 also did not reveal any appreciable changes (Figure 4c ). These results indicate that TM1 expression enhances RhoA protein, which is likely to orchestrate the reorganization of cytoskeleton.
Stability of TM1 induced cytoskeleton
As noted above, the expression of many cytoskeletal proteins (including other TMs), is not completely restored in TM1-expressing DT cells. In addition, TMs are hypothesized to function as dimers; they could form homodimers as well as heterodimers. These and other interactions may not be completely restored in the revertants of DT, notwithstanding the reemergence of micro®laments. Because of these reasons, we investigated whether TM1-induced cytoskeleton is as stable as the one in NIH3T3 cells: one established technique involves treatment of the cells with fungal toxins such as cytochalasins (Warren et al., 1995) . NIH3T3, DT/TM1 and DT/TM1-TM2 cells were incubated with cytochalasin D for dierent time periods and stained for TMs with an antibody (green) and actin (red). In normal NIH3T3 cells, after 5 min of addition of the drug, micro®laments were clearly visible and intact. After 10 min of treatment, although micro®laments were present, they appeared to be less prominent (Figure 5a ). In contrast, in DT/TM1 cells, eects of cytochalasin D were profound; as early as in 5 min, the cells were rounded, with no evidence of any (Figure 5b ). DT/TM1-TM2 cells were more resistant than TM1 alone expressing cells. Cytochalasin D treatment had modest, but readily detectable eects on actin micro®laments in 5 min, which were more pronounced in 10 min ( Figure  5c ). Accumulation of patches of actin along more de®ned structures is evident in 5 min of treatment, while more extensive destruction of cytoskeleton is observed in 10 min. Thus, restoration of TM1 expression is adequate to form micro®laments in DT cells, but these structures are rather labile. However, co-expression of TM2 not only signi®cantly improves the cytoskeletal architecture, but also stabilizes micro®laments. In all of the cell lines, changes in actin staining closely mirrored that of TM. DT and DT/ TM2 cells were not employed in this study, since they lack de®ned micro®laments to begin with.
Rho-kinase pathway
Rho-mediated contractility is critical for the assembly of stress ®bers and focal adhesions (ChrzanowskaWodnicka and Burridge, 1996) . Rho kinase (p160ROCK) is a key eector of Rho-mediated signaling (Matsui et al., 1996; Narumiya et al., 1997) . Among the pathways controlled by P160ROCK, regulation of micro®laments by phosphorylation of myosin light chain kinase and myosin-binding subunit of myosin phosphatase is a prominent one . Therefore, to investigate whether the re-emergence of micro®laments in TM1 expressing cells occurs through Rho kinase directed pathways, we employed two dierent approaches to disrupt possible p160ROCK signaling; transient transfection of DT/ TM1 cells with dominant negative variants of Figure 5 Stability of the cytoskeleton: NIH3T3 cells (a), DT/TM1 (b) and DT/TM1-TM2 (c) were treated with cytochalasin D at 0.5 mg/ml for 5 or 10 min and cells were stained for TMs and actin. Control samples were untreated. Green: TMs as visualized by anti-rabbit second antibody conjugated to FITC; and red: Actin micro®laments by Texas red conjugated phalloidin. DT/TM1 cells had essentially no cytoskeleton by 5 min of treatment and therefore, the 10 min treatment data are not shown. Since the actinstaining and TM staining was essentially identical, only actin pattern was shown for the treatments Tropomyosin-1 induced cytoskeleton V Shah et al p160Rock , and treatment of cells with a speci®c inhibitor of p160ROCK, Y27632 were used (Sahai et al., 1999) . We tested the importance of Rho kinase signaling in maintenance of micro®laments by transient transfection of DT/TM1-TM2 cells with a dominant negative Rho kinase construct, CAT-KD Chihara et al., 1997) . NIH3T3 cells were also transfected with CAT-KD for control purposes. In this experiment, actin ®laments were visualized by staining with phalloidin: simultaneous staining for myc tag allowed the detection of transfected cells (Figure 6a,c) , because the construct was tagged with a myc epitope. As evident from Figure 6b ,d, expression of CAT-KD resulted in a severe disruption of micro®laments in NIH3T3 cells and DT/TM-TM2 cells. CAT-KD expression resulted in aggregation of actin into patches, with a profound decrease in the stress ®bers. Similar results were obtained with DT/ TM1 cells also (data not shown).
Treatment of NIH3T3 cells with 20 mM Y27632 for 15 min did not have signi®cant eects on the cell spreading, but resulted in a decrease of micro®laments as observed by actin staining (Figure 7) . A signi®cant loss of micro®laments and shrinkage of cell mass was, however, evident by 30 min. Tropomyosin staining pattern was identical to that of f-actin in all the cell types also, and hence data are not presented. In DT cells, where no detectable micro®laments are absent, the eects of the drug were less obvious. Incubation with Y27632 for 15 and 30 min resulted in a similar morphology (Figure 7c,d) . The spindle shaped DT cells assumed a round morphology with cytoplasmic extensions containing actin and TMs. In DT/TM1 and DT/TM1-TM2 cells, the eects of the inhibitor were far more extensive. Fifteen minutes of treatment of the drug resulted in severe disruption of micro®la-ment network and cell morphology of the revertants (Figure 7e,g ), although the eects were more pronounced in DT/TM1 cells (Figure 7e ) than in DT/ Under these conditions, however, in DT/TM1 and DT/ TM1-TM2 cells complete disintegration of micro®la-ment network is evident (Figure 7f,h ). These data indicate that p160ROCK signaling is critical in the maintenance of micro®laments induced by TM1.
Discussion
Decreased expression of many actin-binding proteins, including that of TM1, in transformed cells is considered to be a contributing factor of the neoplastic phenotype (Ben-Ze'ev, 1997; Button et al., 1995; Janmey and Chaponnier, 1995) . Restoration of TM1 expression abolishes the malignant phenotype, indicating that TM1 is a class II tumor suppressor (Prasad et al., 1999) . Nevertheless, the underlying pathways involved in cytoskeletal reorganization by TM1 in the transformed cells are not completely understood.
We hypothesized that TM1-induced reversion of the malignant phenotype involves the restructuring of micro®laments and the modulation of signaling pathways controlled by ras oncogene. Reorganization of micro®laments requires participation of many other cytoskeletal proteins. In transformed cells, the levels of other actin-binding proteins, in addition to tropomyosins, are suppressed. In DT/TM1, DT/TM2 and DT/ TM1-TM2 cells, expression of TM1, TM2 and both TMs is restored respectively, but the levels of other cytoskeletal proteins are not experimentally altered. In fact, expression of a-actinin, gelsolin and vinculin which are also known suppressors of transformation (Gluck et al., 1993; Rodriguez Fernandez et al., 1992) are not consistently altered in our revertant cells (data not shown). However, vinculin appeared to organize better in the revertant cells, perhaps re¯ecting improved micro®lament architecture (Figure 2b ). These data are consistent with the earlier reports that TM expression is not altered in the revertants produced by forced expression of either a-actinin or vinculin, thus suggesting the possible modes of reversion of the transformed phenotype by these cytoskeletal proteins could be distinct (Gluck et al., 1993; Rodriguez Fernandez et al., 1992) .
A more notable and signi®cant change is that caldesmon expression is speci®cally restored in TM1-expressing cells, but not in TM2 expressing transformed DT/TM2 cells, thus pointing to interactions between TM1 and caldesmon ( Figure 3 ). Several lines of evidence suggest that caldesmon, which undergoes mitosis-speci®c phosphorylation and binds to actin in Ca 2+ /calmodulin-regulated fashion, functions synergistically with TMs to modulate the integrity of actin cytoskeleton (Huber, 1997; Matsumura and Yamashiro, 1993) ; ®rst, TMs and caldesmon together inhibit the gel severing activity of gelsolin (Ishikawa et al., 1989a,b) ; second, TMs and caldesmon enhance each others binding to actin (Ishikawa et al., 1998; Novy et al., 1993) ; third, caldesmon preferentially increases TM1-binding to actin when compared with that of other TM isoforms with actin (Pittenger et al., 1995) ; fourth, fascin binding with actin is shown to be completely inhibited by caldesmon and TMs together, but little or no eects were observed with either protein alone (Ishikawa et al., 1998) ; and, ®fth, caldesmon when phosphorylated, or bound by calmodulin, dissociates from actin. This results in weakening of TM-actin association, exposing actin ®laments to the action of gel-severing proteins (Pittenger et al., 1995) . Furthermore, increased expression of caldesmon stabilizes micro®laments (Warren et al., 1995 (Warren et al., , 1996 , and caldesmon levels are decreased in many transformed cells, as shown in Figure 3 , and by others (Button et al., 1995; Novy et al., 1991) . More recent studies implicate caldesmon in the regulation of actomyosin contractility and adhesion-dependent signaling in ®broblasts (Helfman et al., 1999) .
TM1-induced cytoskeleton in DT cells appears to be less stable compared to that in NIH3T3 cells. The entry of several other proteins into the cytoskeletal compartment may also remain impaired in DT/TM1 cells, due to the continued activity of ras oncogene in these cells. However, co-expression of TM2 resulted in a marked improvement both in the organization and stability of cytoskeleton, as judged by the sensitivity to cytochalasin D. It is known that heterodimers of TMs are thermodynamically preferred over homodimers (Jancso and Gracea, 1991) . Our previous studies showed that in DT/TM1 cells, homodimers of TM1 are formed initially (Prasad et al., 1994) . They are presumed to exchange with heterodimers consisting of TM1 and possibly with other low M r TMs, since TM2 and TM3 are nearly lacking in these cells (Prasad et al., 1994) . In DT/TM1-TM2 cells, where both TM1 and TM2 are available, heterodimers of TM1 and TM2 are likely to exist, in addition to homodimers of TM1 and homodimers of TM2 (Shah et al., 1998) . These, dynamic multiple TM associations may exert more stabilizing in¯uence and protect micro®laments. A possible pathway through which TM1 could induce micro®laments and aect the cell phenotype is via Rho directed signaling (Narumiya et al., 1997) . Three dierent lines of evidence support the involvement of Rho proteins in the re-emergence of micro®laments: (1) RhoA expression is enhanced in TM1 expressing cells, but not in the cell lines of DT or DT/ TM2 that exhibit transformed phenotype and lack micro®laments; such changes, however, were not detected in the levels of Rac1 and Cdc42; (2) inhibition of p160ROCK with speci®c inhibitor, Y27632, lead to the dissolution of micro®laments in normal NIH3T3 cells and TM1 expressing derivatives of DT cells; and (3) expression of a dominant negative Rho kinase, CAT-KD, interfered with the micro®lament organization in NIH3T3 and DT/TM1-TM2 cells. The demonstration that RhoA is involved in TM1-induced micro®lament formation complements the earlier ®nding that RhoA pathway may be inactivated in Ras transformation (Izawa et al., 1998) .
Our results are also consistent with previous data utilizing dominant active variants Rho and Rho-kinase that Rho proteins are required for the assembly of stress ®bers (Izawa et al., 1998) . However, our results demonstrating the involvement of Rho proteins in restoration of micro®laments dier with those of other researchers who showed that Rho proteins are required for Ras transformation, and constitutively activated of RhoA could transform the cells Prendergast et al., 1995; Qiu et al., 1995) . Enhanced TM1 expression resulted in elevated RhoA proteins, and micro®laments appears to be assembled via p160ROCK pathway. Thus, in DT cells, oncogenic Ras signaling may be channeled via Rac and Cdc42 to manifest the full malignant phenotype to compensate for decreased Rho, as shown in other systems (Izawa et al., 1998; Moorman et al., 1999) . Another possible explanation is that DT cells are very potently transformed, and the eects of oncogenic Ras signaling could be more intense. For example, DT cells form foci with 580% eciency in anchorage independence assays, and with inoculation of as few as 1000 cells tumor growth can be observed in 7 ± 10 days in tumorigenesis assays (Prasad et al., 1993) . Notwithstanding the highly malignant nature of DT cells, restoration of TM1 expression reverts DT cells. Whether reconstituted RhoA protein is also responsible for inhibition of other downstream signaling of oncogenic Ras in this system is unclear at present, and is under investigation.
Our data indicate that p160ROCK is essential in the assembly of stress ®bers in TM1-induced cytoskeletal reorganization, indicating the similarity between the pathways operating in the revertants and in normal cells. These are likely to include RhoA directed activation of Rho kinase, which in turn stimulates contractility to assemble micro®laments Chrzanowska-Wodnicka and Burridge, 1996) . For example, Y-27632 was shown to disrupt micro®la-ment network in NIH3T3 cells (Sahai et al., 1999) . In addition, transformation and cytoskeletal changes induced by constitutively active RhoA are inhibited by Y27632. The data presented herein suggest that upregulation and activation of the endogenous RhoA is likely to mediate TM1-induced cytoskeletal reorganization. The dominant negative variants of Rho kinase and Y-27632, although appear to elicit dierent morphological eects, are able to disrupt the stress ®bers in the revertants employed in this study.
We propose that TM1-induced stress ®ber assembly occurs via the following model. TM1 induces restoration of RhoA and caldesmon, reorganizes vinculin at the focal adhesions in DT cells. It is likely that the expression of caldesmon could be elevated in the revertant cells under the in¯uence of RhoA. Caldesmon expression is shown to be regulated by SRF (Momiyama et al., 1998) , which in turn is regulated by RhoA (Montaner et al., 1999; Spencer and Misra, 1999; Treisman et al., 1998; Zohar et al., 1998) . Enhanced RhoA levels reactivate p160ROCK pathway, which is essential for maintenance of micro®laments. It is recently demonstrated that multiple factors, including cytoskeletal structures regulate Rho activity (Ren et al., 1999) . Co-expression of TM1 and TM2 signi®cantly improves micro®lament architecture and stability. Whether the restored cytoskeleton is essential in establishing and maintaining a revertant phenotype induced by TM1 is under investigation.
Materials and methods
Cell culture
Culture conditions have been described for all cell lines used in this study (Braverman et al., 1996) . Brie¯y, NIH3T3, DT cells and the derivative cell lines are cultured in DMEM high glucose medium (Life Technologies, Gaithersburg, MD, USA), supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA) in the presence of L-glutamine and penicillin and streptomycin. Cell lines derived from DT were supplemented with appropriate drugs, depending on the selection marker. The medium for DT/TM1 cells contained 200 mg/ml of Geneticin (Life Technologies), while xanthine (250 mg/ml; Sigma Chemical Company, St. Louis, MO, USA) and mycophenolic acid (2.5 mg/ml; Sigma) are present in the culture medium for DT/TM2 and DT/TM1-TM2 cells; in addition, DT/TM1-TM2 cell media also contained G418.
Cytochalasin D (Sigma) was added to medium at (0.5 mg/ ml) to test the stability of micro®laments for indicated times and the cells were processed for immuno¯uorescence experiments, as described below. Rho kinase inhibitor, Y-27632 was generously provided by Yoshitomi Pharmaceutical Industries, Ltd., Japan, and was added to the medium at 20 mM.
Western blotting and immunoprecipitations
Cell lysates were prepared as previously described in 1% NP-40/0.25% deoxycholate containing 50 mM Tris buer pH 7.4 and 0.15 M NaCl, with protease inhibitors (Shah et al., 1998) . 100 mg of protein was subjected to electrophoresis on SDSpolyacrylamide gels and electrophoretically transferred to Nytran (S and S, Keene, NH, USA). Western blotting was performed using antibodies against caldesmon, vinculin, gelsolin, a-actinin, Rac, CDC42 and RhoA proteins with appropriate second antibodies (Amersham Pharmacia Biotech, Piscataway, NJ, USA) and Renaissance chemiluminescence kit (NEN, Boston, MA, USA). The blots were routinely reprobed upon treatment with 2% SDS and 5% 2-mercaptoethanol at 558C with an antibody against atubulin for load control. Immunoprecipitations of cell lysates (250 ± 500 mg of protein) were performed with relevant primary antibodies, and the same primary antibodies were used for detection in Western blotting.
Immunofluorescence
Cells were cultured in Nunc chamber slides, and treated with either cytochalasin D or Rho kinase inhibitor as needed. Cells were gently washed with phosphate buered saline, ®xed in 3.7% paraformaldehyde and extracted in 0.5% Triton X-100 for 15 min. The samples were incubated with the primary antibodies, followed by appropriate FITCconjugated second antibodies (Molecular Probes, Eugene, OR, USA). When necessary the samples were also stained with phalloidin conjugated with Texas Red (Molecular Probes) and mounted in Prolong Antifade (Molecular Probes, Eugene, OR, USA) according to the manufacturer. The samples were viewed with an Olympus laser scanning confocal microscope, or a Zeiss LSM510 confocal microscope (Shah et al., 1998) .
Northern blotting
Total RNA was extracted from cultured cells and probed with a caldesmon cDNA probe. The same blot was stripped and reprobed with bactin cDNA as described earlier to normalize for RNA loading (Prasad et al., 1993) .
Plasmids and transfections
A dominant negative form of Rho kinase, CAT-KD was previously described . pEF-Bos-myc-Rhokinase CAT-KD plasmid was used for transfection of normal NIH3T3 and DT/TM1-TM2 cells using DOTAP (Roche Molecular Biochemicals, Indianapolis, IN, USA), according to the manufacturer's guidelines. Forty eight hours after transfection, the cells were ®xed and processed for immunocytochemistry as described above.
